A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.

Qian Zhao,Bingbing Fu,Nan Lyu,Xiangdong Xu,Guangbiao Huang,Yunlong Tan,Xiufeng Xu, Xuehua Zhang,Xueyi Wang,Zhiqiang Wang,Keqing Li,ZhenYu Hu,Hengfen Li,Hongbo He,Shuang Li,Jingyuan Zhao, Ruifeng He,Hua Guo,Yi Li,Lehua Li,Chuang Yang,Shaohong Zou,Bo Wei,Wenqiang Wang,Ce Chen,Zheng Lu, Shunqiang He, Qian Wang,Jinghua Zhao, Xiaoyue Pan, Zhenyu Pan, Junqing Li,Gang Wang

Journal of affective disorders（2023）

引用 2|浏览31

暂无评分

摘要

This study demonstrated that desvenlafaxine XL 50 mg QD was non-inferior to duloxetine 60 mg QD in efficacy in patients with MDD. Desvenlafaxine had a lower incidence of TEAEs than duloxetine did.

查看译文

关键词

17-item Hamilton Depression Rating Scale,Desvenlafaxine,Duloxetine,Major depressive disorder,Non-inferiority

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要